NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Category
  • Gastric/Esophageal Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date October 21, 2024